<?xml version='1.0' encoding='utf-8'?>
<document id="31250766"><sentence text="Intercycle Unplanned Hospital Admissions Due to Cisplatin-based Chemotherapy Regimen-induced Adverse Reactions: A Retrospective Analysis."><entity charOffset="48-57" id="DDI-PubMed.31250766.s1.e0" text="Cisplatin" /></sentence><sentence text="Cisplatin is a commonly used chemotherapy agent known to induce serious adverse reactions that may require hospital readmission"><entity charOffset="0-9" id="DDI-PubMed.31250766.s2.e0" text="Cisplatin" /></sentence><sentence text=" We aimed to analyze the extent and factors associated with unplanned hospital admissions due to cisplatin-based chemotherapy regimen-induced adverse reactions"><entity charOffset="97-106" id="DDI-PubMed.31250766.s3.e0" text="cisplatin" /></sentence><sentence text="" /><sentence text="Retrospective review of medical records of those patients who received at least one cycle of chemotherapy with cisplatin-based regimen during a six-month period from March to August 2017"><entity charOffset="111-120" id="DDI-PubMed.31250766.s5.e0" text="cisplatin" /></sentence><sentence text="" /><sentence text="Of the 458 patients who received cisplatin during the study period, 142 patients did not meet inclusion criteria"><entity charOffset="33-42" id="DDI-PubMed.31250766.s7.e0" text="cisplatin" /></sentence><sentence text=" The remaining 316 patients had a total of 770 episodes of primary admissions for chemotherapy administration" /><sentence text=" Overall, 187 episodes (24%) of intercycle unplanned hospital admission were recorded of which a major proportion (n=178; 23%) was due to chemotherapy-induced adverse reactions" /><sentence text=" Underweight patients had higher odds of unplanned admission (OR 1" /><sentence text="77, 95% confidence interval [CI] 1" /><sentence text="11 to 1" /><sentence text="77)" /><sentence text=" Significantly, more number of patients with cancers of head and neck and cancers of musculoskeletal were readmitted (p&lt;0" /><sentence text="001)" /><sentence text=" Compared to high-dose cisplatin, low- and intermediate-dose cisplatin had lesser odds of unplanned admission (OR 0"><entity charOffset="23-32" id="DDI-PubMed.31250766.s16.e0" text="cisplatin" /><entity charOffset="61-70" id="DDI-PubMed.31250766.s16.e1" text="cisplatin" /><pair ddi="false" e1="DDI-PubMed.31250766.s16.e0" e2="DDI-PubMed.31250766.s16.e0" /><pair ddi="false" e1="DDI-PubMed.31250766.s16.e0" e2="DDI-PubMed.31250766.s16.e1" /></sentence><sentence text="52 and 0" /><sentence text="77; 95% CI, 0"><entity charOffset="8-10" id="DDI-PubMed.31250766.s18.e0" text="CI" /></sentence><sentence text="31 to 0" /><sentence text="88 and 0" /><sentence text="41 to 1" /><sentence text="45, respectively)" /><sentence text=" Patients without concomitant radiotherapy, drug-drug interaction and initial chemotherapy cycles had lesser odds of unplanned admission (OR 0" /><sentence text="38, 0" /><sentence text="50 and 0" /><sentence text="52; 95% CI, 0"><entity charOffset="8-10" id="DDI-PubMed.31250766.s26.e0" text="CI" /></sentence><sentence text="26 to 0" /><sentence text="55, 0" /><sentence text="25 to 0" /><sentence text="99 and 0" /><sentence text="32 to 0" /><sentence text="84 respectively)" /><sentence text=" Unplanned admissions were mainly due to blood-related (31%) and gastrointestinal (19%) adverse reactions" /><sentence text=" Among chemotherapy regimens, cisplatin monotherapy (34%) and cisplatin with doxorubicin (20%) regimens resulted in a major proportion of unplanned admissions"><entity charOffset="30-39" id="DDI-PubMed.31250766.s34.e0" text="cisplatin" /><entity charOffset="62-71" id="DDI-PubMed.31250766.s34.e1" text="cisplatin" /><entity charOffset="77-88" id="DDI-PubMed.31250766.s34.e2" text="doxorubicin" /><pair ddi="false" e1="DDI-PubMed.31250766.s34.e0" e2="DDI-PubMed.31250766.s34.e0" /><pair ddi="false" e1="DDI-PubMed.31250766.s34.e0" e2="DDI-PubMed.31250766.s34.e1" /><pair ddi="false" e1="DDI-PubMed.31250766.s34.e0" e2="DDI-PubMed.31250766.s34.e2" /><pair ddi="false" e1="DDI-PubMed.31250766.s34.e1" e2="DDI-PubMed.31250766.s34.e1" /><pair ddi="false" e1="DDI-PubMed.31250766.s34.e1" e2="DDI-PubMed.31250766.s34.e2" /></sentence><sentence text="" /><sentence text="These findings highlight risk factors that help identify high-risk patients and suggest that therapy modifications may reduce hospital readmissions due to cisplatin-based chemotherapy-induced adverse reactions"><entity charOffset="155-164" id="DDI-PubMed.31250766.s36.e0" text="cisplatin" /></sentence><sentence text="" /></document>